Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of Subcutaneous SQIN-Furosemide vs IV Furosemide in Healthy Volunteers
NCT07269496Phase 1Completed
- Sponsor
- SQ Innovation, Inc.
- Start
- Feb 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SQIN-furosemide in edema (2 arms), sponsored by SQ Innovation, Inc. Primary endpoint: Absolute bioavailability at 30 days. Started Feb 2026; status: completed.
02
Drugs
SQIN-furosemide
03
Conditions
edema
Beyond the preview
Go deeper on NCT07269496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269496.